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Mycobacterium abscessus infection with that of infections due to other pathogenic NTM species. We identiﬁed 33 patients with NTM infection
post-transplantation, 18 with infection that was diagnosed within the ﬁrst year. Although drug resistance was common among M. abscessus
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oping infection with non-tuberculous mycobacteria (NTM),
environmental pathogens that are responsible for a diverse
group of clinical syndromes and are often associated with a
delay in diagnosis [1,2]. Furthermore, treatment of NTM in-
fections in solid organ transplant (SOT) recipients creates
challenges because of drug–drug interactions and overlapping
drug toxicities [3], with treatment regimens based on obser-
vational data from the non-transplant population [4]. PreviousClinical Microbiology and Infection ©studies of the long-term outcomes of NTM infection among
SOT recipients have been limited to lung transplant population
[5–7], with conﬂicting ﬁndings regarding the relationship be-
tween NTM infection and mortality. The relationship between
NTM infection and mortality among SOT recipients overall
remains undeﬁned.
We recently reported risk factors for NTM infections among
SOT recipients at our institution, demonstrating an 11-fold
increase in the odds of NTM infection among lung transplant
recipients [8]. Among NTM species, Mycobacterium abscessus
presents additional therapeutic challenges, in part due to
intrinsic antimicrobial resistance properties [4]. Our current
objective was to evaluate the relationship of NTM species and
mortality among SOT recipients diagnosed with NTM infection,
across organ transplantation types. We hypothesized that NTM
infection due to M. abscessus would lead to decreased survival
when compared with infections due to all other pathogenic
NTM species. As a secondary objective, we sought to measure
the relationship between NTM infection and survival among allClin Microbiol Infect 2015; 21: 43–47
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of SOT recipients with and without NTM infection diagnosed in
the post-transplantation period.MethodsSubjects
Weperformed a retrospective cohort study of SOT recipients at
the Hospital of the University of Pennsylvania. For the primary
exposure, we identiﬁed all SOT recipients withNTM infection by
cross-referencing records from the organ transplant database
with the clinical microbiology laboratory records for the period
between 1 January 2002 and 1 July 2009. We included all SOT
recipients who either met American Thoracic Society/Infectious
Diseases Society of America (ATS/IDSA) criteria for NTM dis-
ease during the study period (for pleuropulmonary isolates) or
had an NTM organism cultured from a sterile site in association
with a clinical syndrome (for all other isolates) [4]. SOT re-
cipients with evidence of NTM disease and/or colonization
before transplantation were excluded from this study so as to
focus on incident NTM disease post-transplantation.
Data collection
Patient information, including demographics and co-morbidities,
was collected from the Pennsylvania Integrated Clinical and
Administrative Research Database, along with review of
consultation records from the Transplant Infectious Disease
service. The date of diagnosis of infection was deﬁned as the
date of the ﬁrst positive culture in the context of a clinical
syndrome that satisﬁed our diagnostic criteria.
All mycobacteria were identiﬁed by molecular methods, with
variations in themethods over the period of the study. Molecular
probes (GenProbe, San Diego, CA, USA) were used to identify
Mycobacterium kansasii and Mycobacterium avium complex
throughout the study period. For all other mycobacteria, iden-
tiﬁcation was by 500-bp 16S rDNA sequence analysis (MicroSeq,
Applied Biosystems, Carlsbad, CA, USA). As 500-bp 16S rDNA
sequencing cannot distinguish between Mycobacterium chelonae
and M. abscessus, biochemical testing and antimicrobial suscep-
tibility phenotype were used to distinguish between these two
species for most of the study period. A molecular assay to
distinguish between M. chelonae and M. abscessus was used be-
tween 2006 and 2009, in addition to phenotyping [9].
Analysis
For the primary analysis, we constructed Kaplan–Meier survival
curves to compare the survival of patients with NTM infection
caused by M. abscessus, and patients with NTM infection caused
by all other organisms. We chose to right-censor after 3 yearsClinical Microbiology and Infection © 2014 Shenyang Pharmaceutical University. Published by Elsof follow up because of the typical time period required to
complete a treatment course for NTM infection. For all in-
fections, we characterized the number of effective drugs that
were used at the time of therapy initiation, based on suscep-
tibility results that were later obtained.
As a secondary objective, we determined the overall rela-
tionship between NTM infection that was diagnosed in the ﬁrst
year post-transplantation and 3-year survival. For a comparison
group, we selected SOT recipients without NTM infection from
the transplant registry, matched 3 : 1 by date of transplantation
for each patient with early NTM infection. We chose this
approach to account for changes in clinical practices in the
management of SOT recipients that occurred during the study
period. We constructed Kaplan–Meier survival curves to
describe the relationship between early NTM infection and 3-
year mortality post-transplantation, and performed Cox
regression modelling to determine the association between
early NTM infection and survival, adjusting for type of trans-
plantation (lung versus non-lung). We selected additional vari-
ables for the adjusted analysis based on their confounding effect
on the relationship of early NTM infection and survival, which
we deﬁned as a change of 15% or greater in the hazard ratio
when included in the model [10].ResultsSurvival of SOT recipients with M. abscessus infection
versus infection due to other NTM species
We identiﬁed 33 SOT recipients with NTM infection that met
ATS/IDSA criteria post-transplantation, including M. abscessus
(n = 14), M. avium (n = 12), Mycobacterium fortuitum (n = 2),
M. kansasii (n = 2), Mycobacterium marinum (n = 2), and
M. chelonae (n = 1). Sites of infection included pleuropulmonary
(n = 21), disseminated (n = 5), abdominal (n = 3), cutaneous
(n = 2), deep wound (n = 1), and bone (n = 1). The median time
between transplantation and diagnosis of NTM infection was
9.2 months (range 4 days to 12.8 years).
We observed a bimodal distribution in the time between
transplantation and the development of NTM infection. Eigh-
teen of 33 patients were diagnosed with NTM infection within
the ﬁrst year post-transplantation, after a median of 2.2 months
(interquartile range 1.5–4.8 months). In contrast, the median
time to diagnosis of NTM infection among 15 patients that
developed infection after the ﬁrst year post-transplantation was
7.5 years (interquartile range 4.7–9.4 years).
There was no signiﬁcant difference in mortality during the 3-
year period following the diagnosis of infection among SOT
recipients with M. abscessus infection versus all other types of
NTM infections, as shown in Fig. 1 (p 0.64 by log-rank test).evier Ltd. All rights reserved, CMI, 21, 43–47
CMI Longworth et al. Mycobacterial infections after transplant 45Multidrug resistance was commonly observed among 13
M. abscessus isolates for which susceptibility results were
available (Table 1). Although none of the isolates was charac-
terized as susceptible to either imipenem or cefoxitin, ﬁve of
ten isolates demonstrated intermediate susceptibility to imi-
penem, and all 13 isolates demonstrated intermediate suscep-
tibility to cefoxitin. Only clarithromycin and amikacin displayed
consistent in vitro activity against M. abscessus isolates from SOT
recipients.
Sixteen of 33 patients had two active drugs initiated at
diagnosis, and 15 of 33 patients had three or more active drugs
initiated at diagnosis. One patient with M. marinum infection
was treated with minocycline monotherapy, and a second pa-
tient with M. fortuitum infection was treated with azithromycin
and ethambutol, but had a macrolide-resistant infection
demonstrated on susceptibility testing.
Secondary analysis of survival of SOT recipients with
and without NTM infection
To characterize the overall effect of early NTM infection on
survival post-transplantation, we performed a secondary sur-
vival analysis limited to 18 SOT recipients with infection during
the ﬁrst year post-transplantation, and selected a comparison
group of SOT recipients without NTM infection by matching in
a 3 : 1 ratio by date of transplantation (selected from the organ
transplant recipient database). Kaplan–Meier survival curves for
the 3-year period post-transplantation are shown in Fig. 2. At 3
years post-transplantation, 9 of 18 (50%) SOT recipients withFIG. 1. Survival following diagnosis
of non-tuberculous mycobacterial
(NTM) infection, Mycobacterium
abscessus versus other NTM species.
Clinical Microbiology and Infection © 2014 Shenyangearly NTM infection had died, compared with 7 of 54 (13%)
SOT recipients without NTM infection. Among eight of nine
patients with death certiﬁcates available for review, NTM
infection was listed as a contributing factor in three patients,
infections due to other organisms were listed in four patients,
and rejection was listed in two patients.
In a Cox regression model, after adjusting for type of
transplantation (lung versus non-lung), early NTM infection
remained signiﬁcantly associated with decreased survival during
the 3-year period post-transplantation (Table 2). Surprisingly,
lung transplantation was not associated with 3-year mortality in
either unadjusted or adjusted analyses.DiscussionContrary to our hypothesis, we did not observe an increased
mortality among SOT recipients with M. abscessus infection,
compared with SOT recipients with other types of NTM
infection. This ﬁnding was surprising given the high level of
antimicrobial resistance that was observed among M. abscessus
isolates, with only 2 of 13 isolates displaying in vitro susceptibility
to at least three drug classes. The similar survival that we
observed between these groups may be related to the pro-
portion of non-M. abscessus infections that presented with deep
or disseminated infection in this cohort (8), or it may be a
reﬂection of the competing risks for mortality that may occurPharmaceutical University. Published by Elsevier Ltd. All rights reserved, CMI, 21, 43–47
TABLE 1. In vitro susceptibilities of initial Mycobacterium
abscessus isolates from solid organ transplant recipients
(n [ 13)
Drug (no. tested) Sensitive Intermediate Resistant
Clarithromycin (13) 12 0 1
Ciproﬂoxacin (13) 0 0 13
Amikacin (13) 13 0 0
Cefoxitin (13) 0 13 0
Imipenem (10) 0 5 5
Linezolid (13) 2 6 5




HR (95% CI) p-value
Adjusted
HR (95% CI) p-value
Early NTM infection 8.76 (2.69–28.57) <0.001 11.25 (2.74–51.17) 0.002
Lung transplantation 2.21 (0.72–6.77) 0.16 0.46 (0.11–1.85) 0.28
Male sex 0.36 (0.12–1.08) 0.07
Age categories
<45 years Reference
45–55 years 1.48 (0.25–8.85) 0.67
55–65 years 1.65 (0.34–7.94) 0.53
>65 years 0.85 (0.08–9.35) 0.89
Malnutrition 6.43 (2.08–19.86) 0.001 2.46 (0.71–8.59) 0.16
Diabetes mellitus 1.37 (0.46–4.07) 0.58
CMV disease 4.74 (1.45–15.53) 0.01 7.41 (1.77–30.96) 0.006
Abbreviations: CMV, cytomegalovirus; HR, hazard ratio; NTM, non-tuberculous
mycobacterial.
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infection [11].
We observed a clear bimodal distribution in the incidence of
NTM infection post-transplantation. Development of NTM
infection during the ﬁrst year post-transplantation was strongly
associated with decreased survival, which was independent of
organ type. Similar to cytomegalovirus infection, the mechanism
for the impact of early NTM infection on survival may be
multifactorial, including indirect effects exerted through im-
mune modulation [12], transplant rejection [13], or develop-
ment of secondary nosocomial infections [14], as suggested by
our review of death certiﬁcates where they were available.
Our study had several limitations. As a single centre inves-
tigation, generalization of the observed relationships to other
transplant centres with differences in practices may be limited.
In addition, the ATS/IDSA criteria for pleuropulmonary in-
fections have not been validated in the transplant population,
and it is possible in some instances that the isolation of NTMClinical Microbiology and Infection © 2014 Shenyang Pharmaceutical University. Published by Elsorganisms may have represented colonization rather than
infection. In addition, changes in diagnostic approaches evolved
over time, as described in Methods. Death was ascertained
from the clinical records, which may be subject to information
bias if the patients that developed NTM infection were more
likely to be followed within the health system, compared with
patients that had not developed NTM infection. By limiting the
survival analysis to a 3-year time horizon, we attempted to
capture the period when patients are likely to receive their
follow-up care at the institution where transplantation was
performed. Strengths of the study included the use of micro-
biology records to identify patients with NTM infection and the
broad range of transplant procedures performed at our
institution.FIG. 2. Survival post-transplantation
of 18 solid organ transplant re-
cipients with early non-tuberculous
mycobacterial (NTM) infection,
compared with 54 solid organ
transplant recipients without NTM
infection (matched 3 : 1 by date of
transplantation).
evier Ltd. All rights reserved, CMI, 21, 43–47
CMI Longworth et al. Mycobacterial infections after transplant 47In summary, we did not observe a difference in survival
between M. abscessus and non-M. abscessus infections among
SOT recipients. However, NTM infection in the ﬁrst year post-
transplantation negatively inﬂuenced 3-year survival compared
with SOT recipients without NTM infection. Prospective,
multicentre studies are needed to provide an evidence base in
support of the optimal approach for identifying and treating
NTM infections in this complex patient population.Transparency DeclarationThere is no conﬂict of interest for any of the authors.References[1] De Groote MA, Huitt G. Infections due to rapidly growing mycobac-
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